Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Working Capital Changes: 2011-2025

Historic Other Working Capital Changes for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$1.1 million.

  • Adma Biologics' Other Working Capital Changes fell 127.78% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$538,000, marking a year-over-year decrease of 112.12%. This contributed to the annual value of $2.7 million for FY2024, which is 1027.62% up from last year.
  • Per Adma Biologics' latest filing, its Other Working Capital Changes stood at -$1.1 million for Q3 2025, which was down 122.95% from -$501,000 recorded in Q2 2025.
  • Adma Biologics' 5-year Other Working Capital Changes high stood at $4.0 million for Q3 2024, and its period low was -$1.6 million during Q1 2024.
  • Its 3-year average for Other Working Capital Changes is $355,636, with a median of -$112,000 in 2023.
  • As far as peak fluctuations go, Adma Biologics' Other Working Capital Changes soared by 56,704.25% in 2021, and later plummeted by 767.84% in 2024.
  • Adma Biologics' Other Working Capital Changes (Quarterly) stood at -$1.5 million in 2021, then soared by 81.76% to -$277,238 in 2022, then surged by 181.88% to $227,000 in 2023, then tumbled by 767.84% to -$1.5 million in 2024, then tumbled by 127.78% to -$1.1 million in 2025.
  • Its Other Working Capital Changes stands at -$1.1 million for Q3 2025, versus -$501,000 for Q2 2025 and $2.6 million for Q1 2025.